当前位置：
X-MOL 学术
›
J. Allergy Clin. Immunol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
HSCT provides effective treatment for lymphoproliferative disorders in children with primary immunodeficiency.
Journal of Allergy and Clinical Immunology ( IF 14.2 ) Pub Date : 2020-05-01 , DOI: 10.1016/j.jaci.2020.03.043 Giulia Prunotto 1 , Ugonna T Offor 2 , Sujith Samarasinghe 3 , Robert Wynn 4 , Ajay Vora 3 , Ben Carpenter 5 , Claire Gowdy 6 , Kieran McHugh 7 , Kevin P Windebank 8 , Attilio Maria Rovelli 1 , Mary A Slatter 9 , Andrew R Gennery 10 , Paul Veys 11 , Chris M Bacon 12 , Simon Bomken 2 , Giovanna Lucchini 11
Journal of Allergy and Clinical Immunology ( IF 14.2 ) Pub Date : 2020-05-01 , DOI: 10.1016/j.jaci.2020.03.043 Giulia Prunotto 1 , Ugonna T Offor 2 , Sujith Samarasinghe 3 , Robert Wynn 4 , Ajay Vora 3 , Ben Carpenter 5 , Claire Gowdy 6 , Kieran McHugh 7 , Kevin P Windebank 8 , Attilio Maria Rovelli 1 , Mary A Slatter 9 , Andrew R Gennery 10 , Paul Veys 11 , Chris M Bacon 12 , Simon Bomken 2 , Giovanna Lucchini 11
Affiliation
In a national cohort, we demonstrate the safety and efficacy of tailored chemo-immunotherapy followed by RIC HSCT for PID-associated lymphoproliferative disorders in children.
中文翻译：
HSCT为原发性免疫缺陷儿童的淋巴增生性疾病提供有效的治疗方法。
在国家队列研究中，我们证明了针对儿童的PID相关性淋巴增生性疾病，采用定制的化学免疫治疗后进行RIC HSCT的安全性和有效性。
更新日期：2020-05-01
中文翻译：
HSCT为原发性免疫缺陷儿童的淋巴增生性疾病提供有效的治疗方法。
在国家队列研究中，我们证明了针对儿童的PID相关性淋巴增生性疾病，采用定制的化学免疫治疗后进行RIC HSCT的安全性和有效性。
京公网安备 11010802027423号